Email this article PREVALENCE OF SERONEGATIVE HEPATITIS D AMONG PATIENTS WITH CHRONIC VIRALHEPATITIS B
- Authors: Semenov AV1, Semenov AV2
-
Affiliations:
- Pasteur Research Institute of Epidemiology and Microbiology, St. Petersburg, Russia
- Issue: Vol 89, No 6 (2012)
- Pages: 106-109
- Section: Articles
- URL: https://microbiol.crie.ru/jour/article/view/13775
- ID: 13775
Cite item
Full Text
Abstract
Aim. Evaluate prevalence of hepatitis D virus replication markers among patients with chronic viral
hepatitis B (CVHB) with active infection course and pronounced biochemical markers of liver damage (ALT
level increase). Materials and methods. ALT>2N served as a criteria of active CVHB course. The following
parameters were determined: HBsAg, anti-HBcor IgG, anti-HBeAb, anti-HCV IgG, anti-HDV IgG+IgM,
HBV DNA, HDV RNA. HCV IgG(+) patients were excluded from the analysis. In total 142 patients were
examined. Results. Antibodies against HDV were detected in 16.2% (n=23) with CVHB, and HDV DNA was
detected in 21.8% of the examined individuals (n=31). The following variants of HDV infection marker
combination were detected: HDV IgG(-) HDV RNA(-) - 75.3% (n=107), no HDV infection; HDV IgG(+)
HDV RNA(-) - 2.8% (n=4), anamnestic antibodies against HDV; HDV IgG(+) HDV RNA (+) - 13.4%
(n=19), active CVHB+D infection; HDV IgG(-) HDV RNA(+) - 8.4% (n=12), seronegative course of
CVHB+B. Conclusion. Examination of patients with pronounced cytolytic syndrome but PCR HBV DNA
(-) must include not only determination of serologic markers of HDV infection but also HDV replication
markers (PCR HDV RNA). Detection of patients with seronegative HDV course among patients with HVHB
(8.4%) persuasively demonstrates the necessity to introduce molecular-biological examination for HDV RNA
into CVHB laboratory diagnostics algorithm.
hepatitis B (CVHB) with active infection course and pronounced biochemical markers of liver damage (ALT
level increase). Materials and methods. ALT>2N served as a criteria of active CVHB course. The following
parameters were determined: HBsAg, anti-HBcor IgG, anti-HBeAb, anti-HCV IgG, anti-HDV IgG+IgM,
HBV DNA, HDV RNA. HCV IgG(+) patients were excluded from the analysis. In total 142 patients were
examined. Results. Antibodies against HDV were detected in 16.2% (n=23) with CVHB, and HDV DNA was
detected in 21.8% of the examined individuals (n=31). The following variants of HDV infection marker
combination were detected: HDV IgG(-) HDV RNA(-) - 75.3% (n=107), no HDV infection; HDV IgG(+)
HDV RNA(-) - 2.8% (n=4), anamnestic antibodies against HDV; HDV IgG(+) HDV RNA (+) - 13.4%
(n=19), active CVHB+D infection; HDV IgG(-) HDV RNA(+) - 8.4% (n=12), seronegative course of
CVHB+B. Conclusion. Examination of patients with pronounced cytolytic syndrome but PCR HBV DNA
(-) must include not only determination of serologic markers of HDV infection but also HDV replication
markers (PCR HDV RNA). Detection of patients with seronegative HDV course among patients with HVHB
(8.4%) persuasively demonstrates the necessity to introduce molecular-biological examination for HDV RNA
into CVHB laboratory diagnostics algorithm.
About the authors
A V Semenov
Pasteur Research Institute of Epidemiology and Microbiology, St. Petersburg, RussiaPasteur Research Institute of Epidemiology and Microbiology, St. Petersburg, Russia
A V Semenov
References
- Левитан Б.Н., Дедов А.В. Дельта-гепатит. Астрахань, АГМА, 2001.
- Семенов А.В., Вашукова С.С., Рахманова А.Г. Предварительные итоги лабораторной диагностики вирусных гепатитов В и С в рамках приоритетной национальной программы Здоровье в Санкт-Петербурге. Медикобиологические и социально-психологические проблемы безопасности в чрезвычайных ситуациях. 2010, 3: 61-64.
- Семенов А.В., Вашукова С.С. Распространенность латентного (HBsAg-негативного) хронического гепатита В среди пациентов кабинетов инфекционных заболеваний по- ликлиник Санкт-Петербурга. Журн. микробиол. 2011, 3: 90-94.
- Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М., ВУНМЦ МЗ РФ, 2003.
- Cross T.J.S., Rizzi P., Horner M. et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J. Med. Virol. 2008, 80: 277-282.
- Hadziyannis S.J. Decreasing prevalence of hepatitis D virus infection. J. Gastroenterol. Hepatol. 1997, 12: 745-746.
- Hsieh T.H., Liu C.J., Chen D.S. et al. Natural course and treatment of hepatitis D virus infection. J. Formos. Med. Assoc. 2006, 105: 869-881.
- Pollicino T., Raffa G., Santantonio T. et al. Replicative and Transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J. Virol. 2011, 85: 432-439.
- Rizzetto M., Ponzetto A., Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990, 8: 10-14.
- Sagnelli E., Stroffolini T., Ascione A. et al. Decrease in HDV endemicity in Italy. J. Hepatol. 1997, 26: 20-24.
- Smedile A., Lavarini C., Farci P. et al. Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy. Am. J. Epidemiol. 1983, 117: 223-229.
- Wedemeyer H., Heidrich B., Manns M.P. Hepatitis D virus infection-not a vanishing disease in Europe! Hepatology. 2007, 45: 1331-1332.
- Wedemeyer H., Manns М. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat. Rev. Gastroenterology Hepatol. 2010, 7: 31-40.
Supplementary files
